UPDATE: Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $35 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to UPDATE: Aldeyra Therapeutics (ALDX) PT Raised to 'Street High' $35 at Canaccord Genuity
September 28, 2018 5:34 AM EDT
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $13.75 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering... More
September 26, 2018 9:33 AM EDT
Cantor Fitzgerald analyst Elemer Piros raised the price target on Aldeyra Therapeutics (NASDAQ: ALDX) to $30.00 (from $23.00) while maintaining an Overweight rating. The new price target is a 'Street High'.
Prios commented, "We are reiterating our OW rating and raising our 12-month PT to... More
September 26, 2018 7:01 AM EDT
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) today announced positive results from its Phase 2b clinical trial of topical ocular reproxalap in patients with dry eye disease.
"The early onset and broad activity observed in the Phase 2b clinical trial suggests that reproxalap could be an... More
